arrow_back Back Filing freshness 10-K Q4 FY2025 SEC EDGAR

Celularity Inc

CELU
$0.69 ▼ -0.01 (-1.96%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
30 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
41
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Celularity Inc faces fundamental challenges. On the positive side, Return on Common Equity (%) remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap
Dividend Yield
Revenue Growth -77.4%
Op. Margin None
ROIC 45.8%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.10M
↓ -77.4%
Net Income Profit after all expenses
$-24.36M
↓ -83.3%
Operating Margin Operating profit as % of sales
-244.1%
↑ +11.7% 0th
FCF / Share Free cash flow per share
$-0.16
↓ -279.5%
Long-Term Debt Long-term obligations
$17.03M
↑ +258.8%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns
100
Financial Health
22
Cash Quality
27

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters